Search research articles
Contact Us
Filters
Showing results (91-100 of 129) with videos related to
Page
of 13
Sort By:
ESMO Open
|
November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
Matteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
Breast Cancer Research and Treatment
|
March 13, 2013
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
Alvaro Moreno-Aspitia, Amylou C Dueck, Ismael Ghanem-Cañete, et al.
Cancer
|
June 8, 2013
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831
Alvaro Moreno-Aspitia, David W Hillman, Stephen H Dyar, et al.
The AAPS Journal
|
June 17, 2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
Isabelle Gingras, Eileen Holmes, Evandro De Azambuja, et al.
Diagnostics (Basel, Switzerland)
|
May 14, 2025
The Clinical Significance of Abnormal Electroencephalography (EEG) Patterns in Patients with Neuropsychiatric Disorders Due to Anti-NMDA Receptor Encephalitis: A Comparative Study
Alvaro Moreno-Avellán, Arely Juarez-Jaramillo, Maria Del Carmen Fernandez Gonzalez-Aragon, et al.
Breast Cancer Research and Treatment
|
November 8, 2023
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
Diogo Martins-Branco, Marie Kassapian, Véronique Debien, et al.
British Journal of Cancer
|
March 24, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
Daniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, et al.
Plos One
|
April 15, 2016
Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors
Nadine Norton, Pooja P Advani, Daniel J Serie, et al.
Journal of Clinical Pharmacology
|
December 6, 2019
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
Manish R Sharma, Shailly Mehrotra, Elizabeth Gray, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 129) with videos related to
Sort By:
Page
of 13
ESMO Open
|
November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
Matteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
Breast Cancer Research and Treatment
|
March 13, 2013
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
Alvaro Moreno-Aspitia, Amylou C Dueck, Ismael Ghanem-Cañete, et al.
Cancer
|
June 8, 2013
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831
Alvaro Moreno-Aspitia, David W Hillman, Stephen H Dyar, et al.
The AAPS Journal
|
June 17, 2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial
Isabelle Gingras, Eileen Holmes, Evandro De Azambuja, et al.
Diagnostics (Basel, Switzerland)
|
May 14, 2025
The Clinical Significance of Abnormal Electroencephalography (EEG) Patterns in Patients with Neuropsychiatric Disorders Due to Anti-NMDA Receptor Encephalitis: A Comparative Study
Alvaro Moreno-Avellán, Arely Juarez-Jaramillo, Maria Del Carmen Fernandez Gonzalez-Aragon, et al.
Breast Cancer Research and Treatment
|
November 8, 2023
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
Diogo Martins-Branco, Marie Kassapian, Véronique Debien, et al.
British Journal of Cancer
|
March 24, 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
Daniel Eiger, Noam F Pondé, Dominique Agbor-Tarh, et al.
Plos One
|
April 15, 2016
Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors
Nadine Norton, Pooja P Advani, Daniel J Serie, et al.
Journal of Clinical Pharmacology
|
December 6, 2019
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
Manish R Sharma, Shailly Mehrotra, Elizabeth Gray, et al.
Page
of 13